COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00957047
Recruitment Status : Completed
First Posted : August 12, 2009
Results First Posted : August 5, 2013
Last Update Posted : July 2, 2014
Information provided by (Responsible Party):
Bial - Portela C S.A.

Brief Summary:
The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy in patients with refractory partial epilepsy over a 12-week maintenance period. Patients who complete Part I may enter a 1-year open-label extension.

Condition or disease Intervention/treatment Phase
Partial Epilepsy Drug: eslicarbazepine acetate Drug: placebo Drug: ESL - Part II Phase 3

Detailed Description:

Part I was a 22-week parallel-group, randomized, placebo-controlled period (8 weeks baseline, 2 weeks double-blind titration, and 12 weeks maintenance). After completing the baseline period, patients were randomized in a 1:1:1:1 ratio to 1 of the 3 ESL dose levels or to placebo.

Part II was a 1-year open-label extension for patients who had completed Part I. The starting dose was 800 mg once daily and could be titrated up or down at 400-mg intervals between 400 and 1200 mg.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 395 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial
Study Start Date : July 2004
Actual Primary Completion Date : August 2006
Actual Study Completion Date : January 2008

Arm Intervention/treatment
Experimental: ESL 400 mg once daily
Eslicarbazepine acetate (ESL) was supplied in 400 mg tablets for Part I
Drug: eslicarbazepine acetate
oral tablets
Other Name: Zebinix

Experimental: ESL 800 mg once daily
Eslicarbazepine acetate (ESL) was supplied in 800-mg tablets for Part I
Drug: eslicarbazepine acetate
oral tablets
Other Name: Zebinix

Experimental: ESL 1200 mg once daily
Eslicarbazepine acetate (ESL) was supplied in 400-mg and 800-mg tablets for Part I
Drug: eslicarbazepine acetate
oral tablets
Other Name: Zebinix

Placebo Comparator: placebo
Placebo tablets matching the 400-mg and 800-mg active substance tablets were supplied
Drug: placebo
once daily placebo comparator
Other Name: Sugar pill

Experimental: ESL - Part II
All patients in Part II (Open-label Extension ) received ESL on an open-label basis, starting at 800 mg once daily.
Drug: ESL - Part II
Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.
Other Name: Eslicarbazepine acetate (ESL), BIA 2-093

Primary Outcome Measures :
  1. PART I - Seizure Frequency [ Time Frame: 12-week maintenance period ]
    The primary efficacy endpoint is the natural log transformation of the seizure frequency per 4 weeks. The primary efficacy analysis was based on the ITT population. Efficacy analyses were performed chiefly using data from the 12-week maintenance period in Part I of the study. The primary efficacy variable is the ln transformation of the seizure frequency per 4 weeks. Seizure frequency was compared between each active treatment group and the placebo group using an ANCOVA that models seizure frequency as a function of baseline seizure frequency and treatment.

  2. PART II - Nº of Treatment-Emergent Adverse Events (TEAE) [ Time Frame: 1 year ]
    Safety assessments were based primarily on AEs (Number of patients who experienced at least one AEs), and on whether these were related to the study medication, were serious, led to permanent discontinuation of study participation, or led to death.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • written informed consent signed by patient
  • aged 18 years or more
  • documented diagnosis of simple or complex partial seizures with or without secondary generalisation since at least 12 months prior to screening
  • at least 4 partial seizures in each 4 week period during the last 8 weeks prior to screening, currently treated with 1 or 2 AEDs (any except oxcarbazepine and felbamate), in a stable dose regimen during at least 2 months prior to screening (patients using vigabatrin should have been on this medication for at least 1 year with no deficit in visual field identified)
  • excepting epilepsy, patient is judged to be in general good health based on medical history, physical examination and laboratory tests
  • post-menopausal or otherwise incapable of becoming pregnant by reason of surgery or tubal ligation; in case of woman of childbearing potential, patient must present a serum beta-hCG test consistent with a non-gravid state and agree to remain abstinent or use reliable contraception (oral contraception should be combined with a barrier method

Exclusion Criteria:

  • only simple partial seizures with no motor symptomatology (classified as A2-4 according to the International Classification of Epileptic Seizures) that are not video-EEG documented
  • primarily generalised epilepsy
  • known rapid progressive neurological disorder; history of status epilepticus or cluster seizures (i.e., 3 or more seizures within 30 minutes) within the 3 months prior to screening
  • seizures of psychogenic origin within the last 2 years
  • history of schizophrenia or suicide attempt
  • currently on or with exposure to felbamate or oxcarbazepine more within one month of screening
  • using benzodiazepines on more than on an occasional basis (except when used chronically as AED)
  • previous use of ESL or participation in a clinical study with ESL
  • known hypersensitivity to carbamazepine, oxcarbazepine or chemically related substances
  • history of abuse of alcohol, drugs or medications within the last 2 years
  • uncontrolled cardiac, renal, hepatic, endocrine, gastrointestinal, metabolic, haematological or oncology disorder
  • second or third-degree atrioventricular blockade not corrected with a pacemaker
  • relevant clinical laboratory abnormalities

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00957047

Layout table for location information
Bial - Portela & Cª, S.A.
S. Mamede do Coronado, Portugal, 4745-457
Sponsors and Collaborators
Bial - Portela C S.A.
Layout table for investigator information
Principal Investigator: Elinor Ben-Menachem, MD Sahlgren University Hospital, Göteborg, Sweden
Principal Investigator: Alberto Alain Gabbai, MD Rua Pedro de Toledo 655, Vila Clemento, Sao Paulo, Brazil
Layout table for additonal information
Responsible Party: Bial - Portela C S.A. Identifier: NCT00957047    
Other Study ID Numbers: BIA-2093-302
First Posted: August 12, 2009    Key Record Dates
Results First Posted: August 5, 2013
Last Update Posted: July 2, 2014
Last Verified: June 2014
Keywords provided by Bial - Portela C S.A.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Eslicarbazepine acetate
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action